Contribute Try STAT+ Today

Liquid biopsies have been a long time coming. After more than two decades of research, the first of these blood tests — which can reveal the presence of cancer-causing genetic mutations the way a tissue sample can — has finally been approved for helping physicians make treatment decisions for cancer patients.

But the bigger ambition for these tests, being pursued by several dozen companies, is using them to screen people and detect cancer early — before it spreads — by analyzing bits of DNA and other molecules shed by tumor cells.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.